TNXP - Tonix Pharmaceuticals Holding Corp. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

TNXP

TONIX PHARMACEUTICALS HOLDING CORP.

NASDAQ

$13.59

▲ UP 0.22% (0.03)

KEY STATISTICS

Market Cap$216.64 M

52w High$31.55

52w Low$9.40

Dividend Yield—

Frequency—

P/E-1.05

Volume490.10K

Shares Out.15.94M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Seth Lederman

COMPENSATION 2026

Salary$702,000

Stock Awards$0

Incentive Plan Pay$0

All Other Comp.$0

Total$3,168,830

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 10, 2012

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

142

PRICE TARGET

Target High$27.00

Target Low$27.00

Target Median$27.00

Target Consensus$27.00

UPCOMING EARNINGS

DateNov 9, 2026

DayMonday

Rev. Est.$16.16M

NOV

MON

SPLIT RECORD

DATE	TYPE	RATIO
2025-02-05	Reverse	1:100
2024-06-10	Reverse	1:32
2023-05-10	Reverse	4:25
2022-05-17	Reverse	1:32
2019-11-01	Reverse	1:10
2018-11-28	Reverse	1:10
2017-03-17	Reverse	1:10
2013-05-01	Reverse	1:20

PRICE

$13.59 ▲ UP 0.22% (+$0.03)

OVERLAYS

About Tonix Pharmaceuticals Holding Corp.

https://www.tonixpharma.com ↗

Tonix Pharmaceuticals is a clinical-stage biopharma developing therapeutics and diagnostics across immunology, rare, infectious, and CNS diseases, including biologics, vaccines, and small molecules for conditions like autoimmune disorders, COVID-1...

INDUSTRY

Biotechnology

A PRODUCT TONIX PHARMACEUTICALS HOLDING CORP. IS KNOWN FOR

Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets)

Tonmya™ is the first FDA-approved non-opioid, sublingual tablet for fibromyalgia, improving sleep quality, and marks a key focus for Tonix Pharmaceuticals' upcoming commercial launch.